INmune Bio, Inc. (NASDAQ: INMB), an immunology company
focused on developing treatments that harness the patient’s innate immune
system to fight disease, today announced its financial results for the second
quarter ended June 30, 2019 and also provided a year-to-date business update.
“This year we remained focused on advancing our pipeline,” INmune Bio CEO RJ
Tesi, M.D., said in the news release. “More recently we announced we have begun
planning a Phase II trial for INB03 after receiving positive preliminary data
from its clinical Phase I study. This preliminary data has allowed us to move
forward with the development of INB03 as a combination immunotherapy for
patients with cancer. We anticipate our full data set to be reported later this
year followed by a Phase II study.”
To view the full press release, visit http://ibn.fm/AQw2d
About INmune Bio, Inc.
INmune Bio, Inc. is a publicly traded (NASDAQ: INMB)
clinical-stage biotechnology company developing therapies targeting the innate
immune system to fight disease. INmune Bio is developing three product
platforms: two products that reengineer the patient’s innate immune system’s
response to cancer and one product to treat neuroinflammation that is currently
focused on Alzheimer’s disease. INKmune is a natural killer (“NK”) cell
therapeutic that primes the patient’s NK cells to attack minimal residual
disease, the remaining cancer cells that are difficult to detect, which often
cause relapse. INB03 inhibits myeloid derived suppressor cells (“MDSC”), which
often cause resistance to immunotherapy, such as anti-PD-1 checkpoint
inhibitors. XPro1595 targets neuroinflammation, which causes microglial
activation and neuronal cell death. INmune Bio’s product platforms utilize a
precision medicine approach for the treatment of a wide variety of hematologic
malignancies, solid tumors and chronic inflammation. To learn more, please
visit www.INmuneBio.com.
NOTE TO INVESTORS: The latest news and updates
relating to INMB are available in the company’s newsroom at http://ibn.fm/INMB
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php

No comments:
Post a Comment